Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries NKGen Biotech, Inc. - Common Stock (NQ: NKGN ) 0.4014 +0.0014 (+0.35%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about NKGen Biotech, Inc. - Common Stock NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial September 12, 2024 From NKGen Biotech Via GlobeNewswire NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From NKGen Biotech Via GlobeNewswire NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report August 22, 2024 From NKGen Biotech, Inc. Via GlobeNewswire NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference July 30, 2024 From NKGen Biotech Via GlobeNewswire NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference July 18, 2024 From NKGen Biotech Via GlobeNewswire NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors July 15, 2024 From NKGen Biotech Via GlobeNewswire NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 June 12, 2024 From NKGen Biotech Via GlobeNewswire Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL May 24, 2024 Via AB Newswire Topics Artificial Intelligence Exposures Artificial Intelligence Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies February 07, 2024 Via Get News Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies February 07, 2024 New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those... Via TheNewswire.com NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial December 30, 2023 Via Get News NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial December 29, 2023 SANTA ANA, Calif., Dec. 29, 2023 - (Plato / Amplifi via 500NewsWire) -- NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient... Via TheNewswire.com NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment. October 24, 2023 Via Get News Exposures Product Safety NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment. October 24, 2023 SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics,... Via TheNewswire.com Exposures Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.